BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang M, Leung NH, Ip M, You JHS. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PLoS One. 2018;13:e0201539. [PMID: 30048534 DOI: 10.1371/journal.pone.0201539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Bajaj JS, Acharya C, Sikaroodi M, Gillevet PM, Thacker LR. Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. GastroHep 2020;2:79-86. [PMID: 33071650 DOI: 10.1002/ygh2.390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Stalder T, Kapel N, Diaz S, Grenouillet F, Koch S, Limat S, Daval F, Vuitton L, Nerich V. A systematic review of economic evaluation in fecal microbiota transplantation. Infect Control Hosp Epidemiol 2020;41:458-66. [DOI: 10.1017/ice.2019.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Giau VV, Lee H, An SSA, Hulme J. Recent advances in the treatment of C. difficile using biotherapeutic agents. Infect Drug Resist 2019;12:1597-615. [PMID: 31354309 DOI: 10.2147/IDR.S207572] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Abdali ZI, Roberts TE, Barton P, Hawkey PM. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection. EClinicalMedicine 2020;24:100420. [PMID: 32637898 DOI: 10.1016/j.eclinm.2020.100420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 You JHS, Jiang X, Lee WH, Chan PKS, Ng SC. Cost‐effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2020;35:1515-23. [DOI: 10.1111/jgh.15002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
6 Hu Y, Xiao HY, He C, Lv NH, Zhu L. Fecal microbiota transplantation as an effective initial therapy for pancreatitis complicated with severe Clostridium difficile infection: A case report. World J Clin Cases 2019; 7(17): 2597-2604 [PMID: 31559298 DOI: 10.12998/wjcc.v7.i17.2597] [Reference Citation Analysis]
7 Dehlholm-Lambertsen E, Hall BK, Jørgensen SMD, Jørgensen CW, Jensen ME, Larsen S, Jensen JS, Ehlers L, Dahlerup JF, Hvas CL. Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection. Therap Adv Gastroenterol 2019;12:1756284819843002. [PMID: 31007720 DOI: 10.1177/1756284819843002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Reference Citation Analysis]